Vitamin D3 + K2: The Calcium Routing Problem Nobody Talks About

Vitamin K2 (menaquinone) activates two proteins that together form a calcium routing system.

The first is osteocalcin — produced by osteoblasts (bone-building cells). In its activated (carboxylated) form, osteocalcin binds calcium and incorporates it into the hydroxyapatite crystal matrix of bone tissue. Without K2, osteocalcin remains in its uncarboxylated form — produced but non-functional, unable to direct calcium into bone.

The second is matrix Gla protein (MGP) — produced by vascular smooth muscle cells. MGP's job is the opposite of osteocalcin's: it inhibits calcium deposition in soft tissues. Specifically, activated MGP prevents calcium from crystallizing in arterial walls, heart valves, and kidney tissue. Like osteocalcin, MGP requires K2-dependent carboxylation to function.

The picture is now clear. D3 brings calcium into the bloodstream. K2-activated osteocalcin pulls calcium into bones. K2-activated MGP keeps calcium out of arteries. Without K2, you have elevated serum calcium with no routing — and the calcium deposits where physics and concentration gradients dictate, which includes arterial walls.

This isn't theoretical. The Rotterdam Study found that high K2 intake was associated with a 57% reduction in cardiac mortality, independent of other cardiovascular risk factors. Multiple subsequent studies have confirmed that arterial calcification correlates inversely with K2 status.

The practical implication: supplementing D3 at high doses without K2 may improve bone mineralization while accelerating vascular calcification. You're solving one problem by creating another.

Your skin synthesizes vitamin D3 when UVB radiation penetrates the epidermis. But UVB only reaches the surface at sufficient intensity when the solar zenith angle is below approximately 45 degrees. Above roughly 35°N latitude — most of Europe, northern China, Japan, Canada, and the northern US — UVB is insufficient for vitamin D synthesis for significant portions of the year, typically November through March.

If you're based in Southeast Asia, you're in a favorable position — UVB intensity is adequate year-round with adequate sun exposure. But people move. A remote worker who spends January through March in Lisbon (38°N), Berlin (52°N), or London (51°N) isn't synthesizing meaningful D3 from sunlight during those months. Add indoor-dominant lifestyles, SPF use, and air pollution (which filters UVB), and functional D3 deficiency becomes the norm.

This makes supplementation non-optional for anyone living above 35°N for any significant portion of the year — and for many people in equatorial regions who simply don't get adequate unprotected midday sun exposure.

Vitamin D3: 2,000 to 5,000 IU daily for maintenance. Higher doses (up to 10,000 IU daily) may be appropriate for correcting deficiency, ideally guided by 25-hydroxyvitamin D blood levels with a target range of 40 to 60 ng/mL. D3 is fat-soluble — take it with a meal containing dietary fat.

Vitamin K2 (as MK-7): 100 to 200 mcg daily. Sufficient to fully carboxylate osteocalcin and MGP in most individuals.

Critical contraindication: Vitamin K directly antagonizes warfarin and other vitamin K antagonist anticoagulants. If you're on warfarin, do not supplement K2 without explicit medical guidance and INR monitoring. This is a pharmacological certainty, not a precautionary disclaimer.